Metabolite profiling reveals normal metabolic control in carriers of mutations in the glucokinase gene (MODY2)

Diabetes

Volumn 62, Issue 2, 2013, Pages 653-661

  Spégel, Peter ^a   Ekholm, Ella ^a   Tuomi, Tiinamaija ^b,c   Groop, Leif ^a   Mulder, Hindrik ^a   Filipsson, Karin ^a  

^a LUND UNIVERSITY   (Sweden)

^b FOLKHÄLSAN RESEARCH CENTER   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOKINASE; GLUCOSE; HEMOGLOBIN A1C; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; FATTY ACID BLOOD LEVEL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC REGULATION; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; HYPERGLYCEMIA; MALE; METABOLOME; MIDDLE AGED; MUTATION; TRIGLYCERIDES;

EID: 84873026980     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0827     Document Type: Article

References (51)

1. Gat-Yablonski G, Shalitin S, Phillip M. Maturity onset diabetes of the young-review. Pediatr Endocrinol Rev 2006;3(Suppl. 3):514-520
2. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care 2011;34:1878-1884
3. Osbak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 2009;30:1512-1526
4. Velho G, Blanché H, Vaxillaire M, et al. Identification of 14 new glucoki-nase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 1997;40:217-224
5. Stride A, Hattersley AT. Different genes, different diabetes: lessons from maturity-onset diabetes of the young. Ann Med 2002;34:207-216
6. Timsit J, Bellanné-Chantelot C, Dubois-Laforgue D, Velho G. Diagnosis and management of maturity-onset diabetes of the young. Treat Endocrinol 2005;4:9-18
7. Mitchell F. Diabetes: extended genetic testing improves MODY diagnosis. Nat Rev Endocrinol 2012;8:319
8. Schnyder S, Mullis PE, Ellard S, Hattersley AT, Flück CE. Genetic testing for glucokinase mutations in clinically selected patients with MODY: a worthwhile investment. Swiss Med Wkly 2005;135:352-356
9. Owen KR, Skupien J, Malecki MT; CEED3 Consortium. The clinical application of non-genetic biomarkers for differential diagnosis of mono-genic diabetes. Diabetes Res Clin Pract 2009;86(Suppl. 1):S15-S21
10. Zhang GF, Sadhukhan S, Tochtrop GP, Brunengraber H. Metabolomics, pathway regulation, and pathway discovery. J Biol Chem 2011;286:23631-23635
11. Pasikanti KK, Ho PC, Chan ECY. Gas chromatography/mass spectrom-etry in metabolic profiling of biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 2008;871:202-211
12. Wishart DS. Computational approaches to metabolomics. Methods Mol Biol 2010;593:283-313
13. Ekholm E, Shaat N, Holst JJ. Characterization of beta cell and incretin function in patients with MODY1 (HNF4A MODY) and MODY3 (HNF1A MODY) in a Swedish patient collection. Acta Diabetol. 16 July 2011 [Epub ahead of print]
14. Spégel P, Danielsson APH, Bacos K, et al. Metabolomics analysis of a human oral glucose tolerance test reveals fatty acids as reliable indicators of regulated metabolism. Metabolomics 2010;6:56-66
15. Danielsson APH, Moritz T, Mulder H, Spégel P. Development of a gas chromatography/mass spectrometry based metabolomics protocol by means of statistical experimental design. Metabolomics 2012;8:50-63
16. Jonsson P, Johansson ES, Wuolikainen A, et al. Predictive metabolite profiling applying hierarchical multivariate curve resolution to GC-MS data -a potential tool for multi-parametric diagnosis. J Proteome Res 2006;5: 1407-1414
17. Chorell E, Moritz T, Branth S, Antti H, Svensson MB. Predictive metab-olomics evaluation of nutrition-modulated metabolic stress responses in human blood serum during the early recovery phase of strenuous physical exercise. J Proteome Res 2009;8:2966-2977
18. Lehto M, Tuomi T, Mahtani MM, et al. Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defect. J Clin Invest 1997;99:582-591
19. Wiklund S, Johansson E, Sjöström L, et al. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal Chem 2008;80:115-122
20. Shih DQ, Dansky HM, Fleisher M, Assmann G, Fajans SS, Stoffel M. Ge-notype/phenotype relationships in HNF-4alpha/MODY1: haploinsufficiency is associated with reduced apolipoprotein (AII), apolipoprotein (CIII), lipoprotein(a), and triglyceride levels. Diabetes 2000;49:832-837
21. Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 2009;58:2429-2443
22. Preet A, Karve TM, Rizk N, Cheema AK. Metabolomics: approaches and applications to diabetes research. J Diabetes Metab 2012:S6-001
23. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Aroa W, Ed. Geneva, World Health Org., 2011
24. Ellard S, Bellanné-Chantelot C, Hattersley AT; European Molecular Genetics Quality Network (EMQN) MODY group. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008;51:546-553
25. Pearson ER, Velho G, Clark P, et al. beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase mutations. Diabetes 2001;50(Suppl. 1): S101-S107
26. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010;53:2504-2508
27. Fendler W, Borowiec M, Antosik K, et al. HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults. Clin Endocrinol (Oxf) 2011; 75:321-327
28. Berger M, Mönks D, Schmidt H, et al. Are glucokinase mutations associated with low triglycerides? Clin Chem 2005;51:791-793
29. Tinto N, Zagari A, Capuano M, et al. Glucokinase gene mutations: structural and genotype-phenotype analyses in MODY children from south Italy. PLoS One 2008;3:e1870
30. Martin D, Bellanné-Chantelot C, Deschamps I, Froguel P, Robert J-J, Velho G. Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2). Diabetes Care 2008;31:1321-1323
31. Davis EA, Cuesta-Muñoz A, Raoul M, et al. Mutants of glucokinase cause hypoglycaemia-and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Dia-betologia 1999;42:1175-1186
32. Sturis J, Kurland IJ, Byrne MM, et al. Compensation in pancreatic beta-cell function in subjects with glucokinase mutations. Diabetes 1994;43: 718-723
33. Sreenan SK, Cockburn BN, Baldwin AC, et al. Adaptation to hyperglycemia enhances insulin secretion in glucokinase mutant mice. Diabetes 1998;47: 1881-1888
34. Matschinsky FM. Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes 1990;39:647-652
35. Jetton TL, Liang Y, Pettepher CC, et al. Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut. J Biol Chem 1994;269:3641-3654
36. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab 2008;8:532-539
37. Parker HE, Habib AM, Rogers GJ, Gribble FM, Reimann F. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 2009;52:289-298
38. De Vos A, Heimberg H, Quartier E, et al. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. J Clin Invest 1995;96:2489-2495
39. Iynedjian PB, Jotterand D, Nouspikel T, Asfari M, Pilot PR. Transcrip-tional induction of glucokinase gene by insulin in cultured liver cells and its repression by the glucagon-cAMP system. J Biol Chem 1989;264: 21824-21829
40. Iynedjian PB. Mammalian glucokinase and its gene. Biochem J 1993;293:1-13
41. Postic C, Shiota M, Niswender KD, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 1999;274: 305-315
42. Clément K, Pueyo ME, Vaxillaire M, et al. Assessment of insulin sensitivity in glucokinase-deficient subjects. Diabetologia 1996;39:82-90
43. O'Doherty RM, Lehman DL, Seoane J, Gómez-Foix AM, Guinovart JJ, Newgard CB. Differential metabolic effects of adenovirus-mediated glu-cokinase and hexokinase I overexpression in rat primary hepatocytes. J Biol Chem 1996;271:20524-20530
44. O'Doherty RM, Lehman DL, Télémaque-Potts S, Newgard CB. Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 1999;48:2022-2027
45. Agius L. Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks. Diabetes 2009;58:18-20
46. Kozian DH, Barthel A, Cousin E, et al. Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study. Horm Metab Res 2010;42:502-506
47. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000;11:351-356
48. Velho G, Petersen KF, Perseghin G, et al. Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects. J Clin Invest 1996;98: 1755-1761
49. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008;29:351-366
50. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-846
51. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011;13:544-552